{"nctId":"NCT00534833","briefTitle":"Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™","startDateStruct":{"date":"2007-09"},"conditions":["Diphtheria","Tetanus","Pertussis","Hepatitis B","Haemophilus Influenzae Type b"],"count":362,"armGroups":[{"label":"Group 1","type":"EXPERIMENTAL","interventionNames":["Biological: DTaP-HB-PRP~T vaccine","Biological: Oral Polio Vaccine"]},{"label":"Group 2","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Tritanrix-HepB/Hib™","Biological: Oral Polio Vaccine"]}],"interventions":[{"name":"DTaP-HB-PRP~T vaccine","otherNames":[]},{"name":"Tritanrix-HepB/Hib™","otherNames":[]},{"name":"Oral Polio Vaccine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Toddler aged 15 to 18 months of age on the day of inclusion (range: 456 days to 578 days of age inclusive)\n* Participated in the AL203 study and completed the three-dose primary series with either DTaP-HB-PRP\\~T or Tritanrix-HepB/Hib™, and OPV, at 6, 10 and 14 weeks of age\n* Informed consent form signed by one parent or legal representative if appropriate (independent witness mandatory if parent is illiterate)\n* Able to attend all scheduled visits and to comply with all trial procedures\n\nExclusion Criteria:\n\n* Participation in another clinical trial in the 4 weeks preceding the trial vaccination\n* Planned participation in another clinical trial during the present trial period\n* Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term (for more than 2 weeks) systemic corticosteroid therapy within the preceding 3 months\n* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to a vaccine containing the same substances\n* Chronic illness at a stage that could interfere with trial conduct or completion\n* Blood or blood-derived products received in the last 3 months\n* Any vaccination in the 4 weeks preceding the trial vaccination\n* Vaccination planned in the 4 weeks following the trial vaccination\n* Febrile (temperature ≥ 38.0°C) or acute illness on the day of inclusion\n* History of documented diphtheria, tetanus, pertussis, Haemophilus influenzae type b, hepatitis B or poliomyelitis infection(s) (confirmed either clinically, serologically, or microbiologically)\n* Vaccination with a vaccine containing diphtheria, tetanus, pertussis, Haemophilus influenzae type b, hepatitis B, or poliovirus 3 types antigen since the end of the primary series\n* Thrombocytopenia or a bleeding disorder contraindicating intramuscular (IM) vaccination\n* Serious adverse event related to any vaccination in the AL203 study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"15 Months","maximumAge":"18 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Summary of Antibody Persistence and Immunogenicity Booster Response in Participants Who Were Vaccinated With Either DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) or Tritanrix-Hep B/Hib™ Concomitantly With OPV","description":"Immunogenicity was assessed by means of radioimmunoassay (RIA) for anti-Hepatitis B (Hep Bs) and anti-polyribosyl ribitol phosphate (PRP) antibodies, enzyme immunoassay (EIA) for anti-Tetanus, and serum neutralization for anti-Diphtheria.\n\nBooster responses defined as titers ≥ 10 mIU/mL for anti-Hep Bs; ≥ 0.15 μg/mL for anti-PRP; ≥ 0.01 IU/mL for anti-Tetanus and anti-Diphtheria at Day 28 after the third vaccination; Pertussis Toxoid (PT) and Filamentous Hemagglutinin (FHA) 4-fold increase, and individual titers ratio.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"93","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Vaccine Antibodies Following Booster Vaccination With Either DTaP-Hep B-PRP~T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV","description":"Immunogenicity were assessed by means of enzyme immunoassay (EIA) for antibodies to the vaccine antigens 28 days after the Booster vaccination","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.75","spread":null},{"groupId":"OG001","value":"17.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"119","spread":null},{"groupId":"OG001","value":"1352","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.908","spread":null},{"groupId":"OG001","value":"3.76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.4","spread":null},{"groupId":"OG001","value":"103","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.016","spread":null},{"groupId":"OG001","value":"0.013","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.81","spread":null},{"groupId":"OG001","value":"1.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.382","spread":null},{"groupId":"OG001","value":"0.500","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.8","spread":null},{"groupId":"OG001","value":"14.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.11","spread":null},{"groupId":"OG001","value":"6.94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"199","spread":null},{"groupId":"OG001","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":null},{"groupId":"OG001","value":"2.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"233","spread":null},{"groupId":"OG001","value":"117","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting At Least 1 Solicited Injection Site and Systemic Reaction Following Booster Vaccination With Either DTaP-Hep B-PRP-T Concomitantly With Oral Polio Vaccine (OPV) or Tritanrix-Hep B/Hib™ Concomitantly With OPV","description":"Solicited injection site reactions: Tenderness, Erythema, and Swelling; Systemic reactions: Fever (Temperature), Vomiting, Crying, Somnolence, Anorexia, and Irritability.\n\nGrade 3 reactions are defined as: Tenderness - cries when injected limb is moved or the movement of the injected limb is reduced; Erythema and Swelling - ≥ 5cm; Fever - temperature ≥ 39.5ºC; Vomiting - ≥6 episodes per 24 hours; Crying - inconsolable crying for \\>3 hours; Somnolence - sleeping most of the time or difficulty to wake up; Anorexia - refuses ≥3 feeds; and Irritability - inconsolable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"124","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":182},"commonTop":["Injection site pain","Injection site erythemia","Irritability","Upper respiratory tract infection","Pyrexia"]}}}